Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2017-01-15
Target enrollment:
Participant gender:
Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using
fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells.
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. Fulvestrant and bevacizumab may also stop the
growth of breast cancer by blocking blood flow to the tumor. Giving fulvestrant together with
bevacizumab may be an effective treatment for metastatic breast cancer.
PURPOSE: This phase II trial is studying how well giving fulvestrant together with
bevacizumab works in treating patients with metastatic breast cancer.